Common Names: herb of the cross
Researchers investigated the therapeutic potential of Verbena officinalis in managing ischaemic stroke. Significant neuroprotective effects were observed, but further research is needed to understand the bioactive compounds and mechanisms involved. This study may offer insights for developing new treatment strategies.
Verbenalin, found in a medicinal plant, has been shown to reduce the production of amyloid-beta (Aβ) peptide in Alzheimer's disease (AD) animal models. In vitro and in vivo experiments displayed decreased levels of Aβ and tau expression in animals treated with verbenalin. Additionally, verbenalin restored the expression of brain-derived neurotrophic factor (BDNF) in the hippocampus, suggesting it may improve the pathological hallmarks of AD. The findings propose that verbenalin can decrease Aβ formation and aid in treating AD.
A study found that Linn., an herb in Chinese medicine, contains compounds that exhibit anti-Alzheimer's disease (AD) activity. The main chemical components were identified through ultra-performance liquid chromatography-mass spectrometry and subsequently used for molecular docking. The transcriptome analysis revealed that leaves had relatively high expression of the anti-AD compounds, and transcription factors may be involved in their biosynthesis. The study provides insights into the biosynthetic pathway of anti-AD components and the regulation mechanism of active components and furthers the potential of Linn. as a treatment for AD.